Rifampin
Small molecule targets CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5 via activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | RIMACTANE | — | 1973-05-09 – 1976-05-18 | fda.gov ↗ |
| Approved | US (FDA) | RIFADIN | — | 1971-05-21 | fda.gov ↗ |
Trials 364 · started per year
Also used as a comparator or background therapy in 144 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT03326050 Comparator | Feb → Sep 2018 | rhinoscleroma | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT02019875 Comparator | Jun 2014 → Dec 2020 | calcium metabolic disease | University of Washington | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 125 trials | ||||||
| Phase 1 | NCT07058090 Comparator | Jul → Dec 2025 overdue | drug-induced liver injury, tuberculosis | Liaquat National Hospital & Medical College | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07014488 Background | Jun → Aug 2025 | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06194864 Background | Jan → May 2024 | — | Emalex Biosciences Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05592223 Comparator | Dec 2022 → Aug 2023 | tuberculosis | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT05431673 Comparator | Aug 2022 → Jun 2023 | rhinoscleroma | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT05255276 Comparator | Feb → May 2022 | — | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04510649 Background | Jul → Sep 2020 | — | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT04266509 Background | Jun → Sep 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04577885 Background | May → Aug 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04290390 Comparator | Feb 2020 → Jan 2021 | — | TherapeuticsMD | Completed | No outcome recorded |
| Phase 1 | NCT03213145 Background | Jul → Aug 2017 | metabolic dysfunction-associated steatohepatitis | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03186482 Comparator | Jun 2017 → Jan 2018 | HIV infectious disease | St. Stephens Clinical Research | Completed | No outcome recorded |
| Phase 1 | NCT02832778 Background | Nov 2016 → Jan 2018 | HIV infectious disease | St Stephens Aids Trust | Unknown | No outcome recorded |
| Phase 1 | NCT02706535 Background | May 2016 → Jan 2017 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02809768 Background | Apr → Aug 2016 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02729467 Background | Mar → Jun 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02545439 Background | Jul → Oct 2015 | — | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01770392 Comparator | Jan → Mar 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02507167 Comparator | Nov 2012 → Jul 2013 | — | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT01533870 Comparator | Mar → May 2012 | constipation disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01169038 Comparator | Jul → Nov 2010 | pulmonary sarcoidosis | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT01162486 Comparator | Apr 2010 → Feb 2011 | pulmonary tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01406002 Background | Jan → Mar 2010 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01080651 Comparator | Dec 2008 → Mar 2009 | invasive aspergillosis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00621309 Comparator | Mar 2008 → Jun 2010 | — | University of Washington | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06889701 Background | Apr 2025 → Aug 2026 overdue | periprosthetic joint infection | TenNor Therapeutics Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03678688 Comparator | Oct 2018 → Feb 2022 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 246 trials | ||||||
| Phase 2 | NCT07467252 Comparator | Sep 2026 → Dec 2027 expected | pulmonary tuberculosis | Ministry of Health, Saudi Arabia | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07656012 Comparator | Sep 2026 → Sep 2030 expected | tuberculosis | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07595042 Comparator | Jul 2026 → Jun 2029 expected | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07350174 Comparator | Mar 2026 → Mar 2028 expected | meningeal tuberculosis | BioVersys AG | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07303699 Background | Jan 2026 → Mar 2027 expected | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07073638 Background | Oct 2025 → Sep 2026 expected | pulmonary tuberculosis | Thirty Respiratory Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06446245 Background | Aug 2025 → Nov 2027 expected | meningeal tuberculosis | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT07129629 Comparator | Aug 2025 → Dec 2026 expected | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06917495 Comparator | Apr 2025 → Dec 2027 expected | tuberculosis, spinal | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06192160 Background | Mar 2025 → Nov 2026 expected | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT06585020 Comparator | Oct 2024 → Aug 2026 overdue | Mycobacterium xenopi infection, lung disorder | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 2 | NCT06114628 Comparator | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT06199921 Comparator | Jan 2024 → Mar 2026 overdue | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05556746 Comparator | Nov 2023 → Jun 2025 overdue | HIV infectious disease, pulmonary tuberculosis | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06224036 Comparator | Oct 2023 → Mar 2024 | drug-resistant tuberculosis | Beijing Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06058299 Comparator | Oct 2023 → Dec 2024 overdue | pulmonary tuberculosis | Global Alliance for TB Drug Development | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05534750 Comparator | Apr 2023 → Apr 2026 overdue | multidrug-resistant tuberculosis | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT05406479 Comparator | Jul 2022 → Jan 2023 | leprosy | Institute of Tropical Medicine, Belgium | Completed | No outcome recorded |
| Phase 2 | NCT05221502 Comparator | Apr 2022 → Apr 2024 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05169554 Comparator | Dec 2021 → May 2026 | Buruli ulcer disease | Research & Development Agency of Aragón Foundation | Unknown | No outcome recorded |
| Phase 2 | NCT04311502 Comparator | Nov 2021 → Jun 2024 | HIV infectious disease, tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT04930744 Background | Aug 2021 → Apr 2025 | coinfection, pulmonary tuberculosis | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT04553406 Comparator | Dec 2020 → Jan 2021 | Mycobacterium avium complex disease, pulmonary non-tuberculous mycobacterial infection | Spero Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT04504851 Background | Aug 2020 → Mar 2021 | pulmonary tuberculosis | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT04176250 Comparator | Jan 2020 → Oct 2022 | pulmonary tuberculosis | Gates Medical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02381470 Comparator | Feb → Sep 2019 | pulmonary tuberculosis | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 2 | NCT03563599 Comparator | Jul 2018 → Sep 2019 | tuberculosis | Qurient Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02836483 Comparator | Dec 2016 → Jul 2019 | pulmonary tuberculosis | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03281226 Comparator | Dec 2016 → Jun 2019 | AIDS, pulmonary tuberculosis | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Unknown | No outcome recorded |
| Phase 2 | NCT01589497 Comparator | Jun 2015 → Jan 2016 | tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT02279875 Comparator | Nov 2014 → Nov 2016 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT02193776 Comparator | Oct 2014 → Feb 2016 | tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT02024555 Comparator | Mar 2014 → Apr 2019 | sarcoidosis | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT01601626 Comparator | Jul 2013 → Jan 2017 | HIV infectious disease, tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Terminated | No outcome recorded |
| Phase 2 | NCT02121314 Comparator | Jul 2013 → Apr 2014 | tuberculosis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT01802502 Comparator | Jun → Oct 2013 | meningeal tuberculosis | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT01516203 Comparator | Dec 2012 → Dec 2013 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01594827 Background | Oct 2012 → Dec 2017 | cystic fibrosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01225640 Comparator | Aug → Dec 2011 | tuberculosis | Sequella, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01215851 Comparator | Oct 2010 → May 2011 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT00760149 Comparator | Jul 2010 → Sep 2013 | tuberculosis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00814671 Comparator | Apr 2010 → Jun 2013 | tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00728507 Comparator | Nov 2009 → Apr 2013 | tuberculosis | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2 | NCT00694629 Comparator | Dec 2008 → Jun 2013 | pulmonary tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00144417 Background | Feb 2006 → Jun 2007 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00140309 Background | Jul 2003 → Dec 2005 | pulmonary tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT05766267 Comparator | Nov 2023 → Dec 2026 expected | pulmonary tuberculosis | Centers for Disease Control and Prevention | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04721795 Comparator | Jan 2021 → Mar 2022 | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT04630145 Comparator | Jan 2021 → Nov 2024 | Mycobacterium avium complex disease | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2/3 | NCT03474029 Comparator | Aug 2019 → Dec 2029 expected | latent tuberculosis infection | Centers for Disease Control and Prevention | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03672630 Comparator | Feb 2019 → Jan 2026 | Mycobacterium avium complex disease, pulmonary non-tuberculous mycobacterial infection | Kevin Winthrop | Completed | No outcome recorded |
| Phase 2/3 | NCT03338621 Comparator | Jul 2018 → Jul 2021 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2/3 | NCT02467608 Background | Dec 2012 → Jan 2019 | pulmonary tuberculosis | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT00495326 Background | Dec 2007 → Apr 2011 | AIDS, tuberculosis | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 325 trials | ||||||
| Phase 3 | NCT07345325 Comparator | Jun 2026 → Dec 2030 expected | infective endocarditis | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07253688 Comparator | Nov 2025 → Dec 2029 expected | infective endocarditis | Todd C. Lee MD MPH FIDSA | Recruiting | No outcome recorded |
| Phase 3 | NCT06191692 Comparator | Aug 2025 → Dec 2026 expected | latent tuberculosis infection | Freundeskreis Für Internationale Tuberkulosehilfe e.V | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07076225 Comparator | Jul 2025 → Jan 2030 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06905522 Comparator | Jun 2025 → Jan 2029 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06253715 Comparator | Jan 2025 → Sep 2027 expected | lymph node tuberculosis, pulmonary tuberculosis | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT06489431 Comparator | Dec 2023 → May 2026 overdue | erectile dysfunction, prosthesis-related infectious disease | Rush University Medical Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06022146 Comparator | Sep 2023 → Sep 2026 expected | latent tuberculosis infection | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05597280 Comparator | Mar 2023 → Mar 2027 expected | leprosy | Institute of Tropical Medicine, Belgium | Recruiting | No outcome recorded |
| Phase 3 | NCT05454345 Comparator | Oct 2022 → Jun 2025 | pulmonary tuberculosis | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT04672525 Comparator | Nov 2021 → Nov 2026 expected | periprosthetic joint infection | Tourcoing Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04260477 Comparator | Mar 2021 → Jun 2025 overdue | multidrug-resistant tuberculosis, pulmonary tuberculosis | Institute of Tropical Medicine, Belgium | Recruiting | No outcome recorded |
| Phase 3 | NCT03236987 Background | Feb 2018 → Feb 2028 expected | Mycobacterium avium complex disease, respiratory tract infectious disorder | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT02563327 Comparator | May 2016 → Aug 2021 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT02342886 Comparator | Feb 2015 → Jan 2018 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 3 | NCT00170209 Comparator | Aug 2011 → Nov 2014 | latent tuberculosis infection | McGill University | Completed | No outcome recorded |
| Phase 3 | NCT01287221 Comparator | Mar 2011 → Nov 2012 | multiple system atrophy | Phillip Low | Terminated | No outcome recorded |
| Phase 3 | NCT00931736 Comparator | Aug 2009 → Apr 2017 | latent tuberculosis infection | McGill University | Completed | No outcome recorded |
| Phase 3 | NCT00715858 Comparator | May 2008 → Aug 2009 | Alzheimer disease | McMaster University | Unknown | No outcome recorded |
| Phase 3 | NCT00351273 Comparator | May 2006 → Sep 2008 | reactive arthritis | University of South Florida | Completed | No outcome recorded |
| Phase 3 | NCT00698334 Comparator | Apr 2006 → Sep 2010 | AIDS, tuberculosis | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00128206 Comparator | Nov 2004 → Oct 2008 | tuberculosis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00057122 Comparator | Sep 2002 → Nov 2008 | HIV infectious disease, tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 421 trials | ||||||
| Phase 4 | NCT07148960 Background | Sep 2025 → Jul 2027 expected | staphylococcus aureus infection | West Virginia University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07213765 Comparator | Jul 2025 → Sep 2028 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT07084402 Background | Jul 2025 → Jul 2027 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT06771050 Comparator | Mar 2025 → Feb 2028 expected | periprosthetic joint infection | University of Newcastle, Australia | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05021731 Comparator | Apr 2024 → Apr 2025 | kidney failure, latent tuberculosis infection | Miguel Santin | Unknown | No outcome recorded |
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT06403943 Background | May 2023 → Oct 2026 expected | pulmonary tuberculosis | Beijing Chest Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06172010 Comparator | Apr 2023 → Mar 2027 expected | periprosthetic joint infection | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT04921943 Comparator | May 2021 → Dec 2025 overdue | pulmonary non-tuberculous mycobacterial infection | Oregon Health and Science University | Recruiting | No outcome recorded |
| Phase 4 | NCT03278483 Comparator | Feb 2019 | tuberculosis, type 2 diabetes mellitus | National Institute of Public Health, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT03012529 Comparator | Jan 2018 → Nov 2025 | diabetes mellitus, osteomyelitis | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT03561753 Comparator | Dec 2017 → Dec 2019 | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Completed | No outcome recorded |
| Phase 4 | NCT02231229 Comparator | Jul 2014 → Jul 2018 | tuberculosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT02331823 Comparator | Jun 2013 → Dec 2015 | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 4 | NCT01854489 Comparator | Apr 2013 → Nov 2014 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01690104 Comparator | Aug 2012 → Dec 2013 | — | University of Oulu | Completed | No outcome recorded |
| Phase 4 | NCT00985270 Comparator | Sep 2009 → Oct 2010 | glucose intolerance | University of Oulu | Completed | No outcome recorded |
| Phase 4 | NCT02123628 Comparator | Jun 2007 → Jun 2010 | diabetes mellitus | Tourcoing Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00669643 Comparator | Feb 2007 → Sep 2012 | leprosy | University of Brasilia | Completed | No outcome recorded |
| Phase 4 | NCT00423982 Comparator | Apr 2006 → Dec 2012 | periprosthetic joint infection, staphylococcal infection | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00367913 Background | Mar 1995 → Sep 2004 | lung disorder | British Thoracic Society | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT07608172 Comparator | May 2026 → Jun 2028 expected | pulmonary tuberculosis | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| — | NCT05268120 Comparator | Jul 2022 → May 2028 expected | methicillin-resistant staphylococcus aureus infectious disease | Leiden University Medical Center | Recruiting | No outcome recorded |
| — | NCT05046860 Background | Mar 2022 → Aug 2026 overdue | periprosthetic joint infection | Centre Hospitalier Universitaire de Nice | Active not recruiting | No outcome recorded |
| — | NCT04187469 Background | Mar 2020 → Feb 2023 | pulmonary tuberculosis | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT03478033 Comparator | Apr 2018 → Jun 2020 | AIDS, pulmonary tuberculosis | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
| — | NCT03173053 Comparator | Feb 2018 → Oct 2021 | movement disorder, staphylococcus aureus infection | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT02554318 Background | Nov 2013 → Feb 2015 | pulmonary tuberculosis | University of Giessen | Completed | No outcome recorded |
| — | NCT01677871 Comparator | Sep 2012 → Sep 2014 | tuberculosis | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT01269541 Comparator | Mar 2011 → May 2015 | — | Region Skane | Completed | No outcome recorded |
| — | NCT01500837 Comparator | Oct 2010 → Oct 2011 | infective arthritis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT01063270 Comparator | Feb 2010 → Jul 2011 | hidradenitis suppurativa | Henry Ford Health System | Completed | No outcome recorded |
| — | NCT01344148 Background | Feb 2009 → Jun 2011 | AIDS | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
| — | NCT01245036 Comparator | Jan 2009 → Dec 2012 | sarcoidosis, tuberculosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| — | NCT00568711 Comparator | Sep 2006 → Dec 2009 | scrub typhus | Dong-Min Kim | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-05-20 | Daiichi Sankyo | Daiichi Sankyo Receives Approval in Japan for Additional Indication of Rifadin(R) Capsules for Nontuberculous Mycobacterial Disease daiichisankyo.com ↗ |
| 2010-12-15 | Daiichi Sankyo | Daiichi Sankyo Submits Application for Additional Indication of Rifadin(R) Capsules for Nontuberculous Mycobacterial Disease daiichisankyo.com ↗ |
Evidence & citations 39 cited values
Every value below carries the sentence it was read from. 519 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rifampin | “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗252“empiric initiation of the enhanced spectrum antimicrobial therapy regimen (rifampin, isoniazid, linezolid, and levofloxacin) for 14 days plus standard care which includes...” NCT07332325 ↗ “A single dose of 600 mg rifampin, a potent OATP1B1/1B3 inhibitor, did not impact the PK of selatogrel to a clinically relevant extent suggesting that OATP1B1 and OATP1B3...” PMID 32166864 ↗ Mar 2020 “This is a phase II randomized open-label trial of high versus standard dose rifampin (RIF) with or without linezolid (LZD) for the first 4 weeks of treatment for Tuberculosis...” NCT04021121 ↗ “This domain will focus on an antibiotic called rifampicin (also sometimes known as rifampin) as it is often added to other antibiotics to help treat artificial joint infections.” NCT06771050 ↗ “The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.” NCT03561753 ↗ “in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16” NCT04510649 ↗ “using regimens containing isoniazid (INH \[H\]), rifampin (RIF \[R\]), pyrazinamide (PZA \[Z\]), moxifloxacin (MXF \[M\]), and ethambutol (EMB \[E\]).” NCT02371681 ↗ “Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily” NCT01700790 ↗ “Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days.” NCT04553406 ↗ “2 months of isoniazid, rifampin, pyrazinamide, and ethambutol followed by 4 months of isoniazid and rifampin” NCT07608172 ↗ “600 mg of rifampin capsules once daily (QD) in the morning under fasting conditions for 8 consecutive days” NCT07330531 ↗ “or an active control of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) or linezolid 600 mg BID.” PMID 34871098 ↗ Dec 2021 “Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica.” NCT00816426 ↗ “Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)” NCT02957448 ↗ “Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic” NCT01728363 ↗ “subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7” NCT03637790 ↗ “Oral rifampin may be added for participants with prosthetic material.” NCT07148960 ↗ “metronidazole, moxifloxacin, rifampin, trimethoprim-sulfamethoxazole” NCT05977868 ↗ “multiple doses of rifampin 600 mg daily, a strong CYP3A inducer” NCT03258372 ↗ “Sublingual tablet given alone and in conjunction with Rifampin” NCT02545439 ↗ “Day2-7: rifampin 600 mg, once a day oral administration” NCT01080651 ↗ “IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297” NCT04584515 ↗ “* Rifampin IP and PO twice daily, 10mg/kg /12H” NCT02123628 ↗ “Study drugs include trabectedin and rifampin.” NCT01273480 ↗ “* Rifampin (IP an PO) : 10mg/Kg/12h” NCT05074147 ↗ “rifampin [R]: 450~600mg daily” NCT02467608 ↗ “Rifampin as oral capsule” NCT04843540 ↗ “Rifampin=Rifadin” NCT01074554 ↗ “Rifampin” NCT02099240 ↗ |
| Known as | Abrifam | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | BA 41166/E | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | BA 411661E | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Eremfat | “Rifampicin (Eremfat®) 600 mg orally in the evening for 10 days” NCT03082183 ↗1“oral rifampin administration (600 mg EREMFAT®)” NCT02507167 ↗ |
| Known as | L-5103 | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | L-5103 LEPETIT | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | NIH-10782 | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | NSC-113926 | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | RFP | “An open-label, randomized, 4-treatment, 6-sequence, 4-period crossover study was conducted to investigate the effects of rifampicin (RFP), an inhibitor of organic anionic...” PMID 38860384 ↗ Jun 20241“Group B: Rifampicin (RFP) or Rifabutin (RBT) + CAM + EB” NCT04630145 ↗ |
| Known as | RIF | “In this open-labeled, randomized clinical trial, the Investigator will assess the safety and pharmacokinetics (PK) of model-optimized doses of rifampicin (RIF) with or without...” NCT02958709 ↗16“Many people living with human immunodeficiency virus (PLWH) require TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral exposure.” PMID 30084943 ↗ Jan 2019 “Ritonavir-boosted darunavir (DRV/r) and dolutegravir (DTG) are affected by induction of metabolizing enzymes and efflux transporters caused by rifampicin (RIF).” PMID 35583344 ↗ May 2022 “Fusidic acid (FA) has been used for decades for bone infection, including prosthetic joint infection (PJI), often in combination with rifampin (RIF).” PMID 27682068 ↗ Sep 2016 “There is an unmet need for data concerning DTG once daily dosing in the presence of rifampicin (RIF), the widely used anti-tuberculosis antibiotic.” NCT03199690 ↗ “The purpose of this study is to evaluate the potential of high doses of rifampin (RIF) to shorten treatment for tuberculosis (TB)” NCT01408914 ↗ “WHO-recommended treatment requires 8-weeks of daily rifampicin (RIF) and clarithromycin (CLA) with wound care.” PMID 38573915 ↗ Apr 2024 “Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica.” NCT00816426 ↗ “A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF)” NCT07002255 ↗ “Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*.” NCT03474029 ↗ “high dose Rifampicin (RIF)” NCT04521803 ↗ “Drug: Rifampicin (RIF)” NCT05383742 ↗ “rifampin (RIF \[R\])” NCT02371681 ↗ “rifampicin (R /RIF)” NCT02231229 ↗ “Rifampicin (RIF)” NCT07084402 ↗ “Rifampin (RIF)” NCT01571414 ↗ |
| Known as | Rifa | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifadin | “Rifadin 600mg by mouth as two 300mg rifadin capsules” NCT04029584 ↗2“oral rifampicin (Rifadin with 10mg/kg/day)” NCT05821478 ↗ “Drug: Rifadin® (Rifampicin)” NCT03186482 ↗ |
| Known as | Rifadine | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifaldazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifaldin | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifampicin | “Eligible patients were randomly assigned to receive intramuscular streptomycin (15 mg/kg once daily) and oral rifampicin (10 mg/kg once daily) for 8 weeks (8-week streptomycin...” PMID 20137805 ↗ Feb 2010256“INTERVENTIONS: Patients were randomized to receive daily treatment with 4 drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) given as an FDC (n = 798 patients) or...” PMID 21486974 ↗ Apr 2011 “This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol...” NCT06224036 ↗ “Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for...” NCT05046860 ↗ “45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue...” NCT00750841 ↗ “Increased doses of rifampicin (R) to 35±5 mg/kg daily and isoniazid (H) 10±2 mg/kg daily together with standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E)...” NCT04738812 ↗ “FDC intensive phase containing 150 mg of rifampicin, 75 mg of isoniazid not 300mg, 400 mg of pyrazinamide, and 275 mg of ethambutol, while FDC continuation phase containing...” NCT05005637 ↗ “This domain will focus on an antibiotic called rifampicin (also sometimes known as rifampin) as it is often added to other antibiotics to help treat artificial joint infections.” NCT06771050 ↗ “This study aimed to quantify the influence of food on the pharmacokinetics of isoniazid, rifampicin, ethambutol and pyrazinamide in TB patients starting anti-TB treatment.” PMID 26661397 ↗ Dec 2015 “SOC plus 6 months of tuberculosis treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, plus isoniazid and rifampicin for 4 subsequent months)” PMID 42468541 ↗ Jul 2026 “RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months” NCT04117698 ↗ “using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment” PMID 36348453 ↗ Nov 2022 “Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months.” NCT04721795 ↗ “Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained” NCT02153528 ↗ “including rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15 - 20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day” NCT06446245 ↗ “Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight)” NCT03281226 ↗ “Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days” NCT04176250 ↗ “Rifampicin capsules: 0.15 g/capsule. 0.45 g (3 capsules) orally once daily within 1 h before breakfast for 8 weeks (56 days).” NCT06889701 ↗ “Session 3: Identical to Session 1, but following a 10-day pretreatment with rifampicin (CYP2C19 inducer, 600 mg once daily).” NCT07014930 ↗ “Two months of isoniazid (H), ethambutol (E), rifampicin (R) and Pyrazinamide (Z) followed by HR(E) for another two months” NCT06727864 ↗ “Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months” NCT01677871 ↗ “Participants received isoniazid and pyrazinamide plus: (i) high-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, arm 1)” PMID 35291004 ↗ Oct 2022 “Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)” NCT01225640 ↗ “Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol.” NCT04044001 ↗ “We investigated whether dose escalation of atazanavir/ritonavir could safely overcome the DDI with rifampicin.” PMID 37982585 ↗ May 2024 “Isoniazid (5 mg/kg/day); Rifampicin (10 mg/kg/day); Pyrazinamide (30 mg/kg/day); Ethambutol (20 mg/kg/day).” NCT07350174 ↗ “isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets” NCT03338621 ↗ “Isoniazid (H) + rifampicin (R) + pyrazinamide (Z), ethambutol (E) for 8 weeks followed by HR for 18 weeks” NCT06058299 ↗ “INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. \>50 kg) for six months” NCT01245036 ↗ “Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol.” NCT03678688 ↗ “Anti-Tb Therapy: 2HREZ-4HRifb(H:Isoniazid，R:Rifampicin，E:Ethambutol，Z：pyrazinamide，Rifb:Rifabutin)” NCT01344148 ↗ “each tablet containing 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, and 275mg ethambutol” NCT01215851 ↗ “During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, \>71kg 750mg daily” NCT05401071 ↗ “isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)” NCT06041919 ↗ “rifampicin (0.45g for weight 50kg and below, 0.6g for weight 50kg and above)” NCT06403943 ↗ “Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg” NCT02832778 ↗ “Isoniazid (H) , Rifampicin (R), Pyrazinamide (Z) and Ethambutol (E)” NCT06153069 ↗ “Oral dose of omeprazole, voriconazole, itraconazole, or rifampicin” NCT05822544 ↗ “New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg” NCT03862248 ↗ “Standard treatment = Rifampicin, ethambutol and clarithromycin” NCT06585020 ↗ “RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)” NCT03563599 ↗ “8-month regimen of isoniazid, rifampicin, and streptomycin” PMID 29519716 ↗ Mar 2018 “rifampicin 35 mg/kg, with or without moxifloxacin 400 mg” PMID 41612490 ↗ Jan 2026 “Ethambutol; isoniazid; rifampicin; pyrazinamide” NCT04260477 ↗ “Rifampicin, dosage 10mg / kg / day for 7 days” NCT05534750 ↗ “oral rifampicin (Rifadin with 10mg/kg/day)” NCT05821478 ↗ “rifampicin, rifabutin, isoniazid” NCT03237182 ↗ “Single dose of Rifampicin” NCT05406479 ↗ “rifampicin (R /RIF)” NCT02231229 ↗ |
| Known as | Rifampicin = Rifadin | “Rifampicin = Rifadin” NCT00696566 ↗ |
| Known as | Rifampicin Capsules | “Drug: Rifampicin Capsules” NCT02836821 ↗1“rifampicin capsules” NCT02331823 ↗ |
| Known as | Rifampicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifampicine | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifampicinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifampin component of rifamate | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifampin component of rifater | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifampin generic; Brand Rifadin, Rimatane | “Rifampin generic; Brand Rifadin, Rimatane” NCT01728363 ↗ |
| Known as | Rifampin=Rifadin | “Rifampin=Rifadin” NCT01074554 ↗ |
| Known as | Rifamycin amp | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifapiam | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifaprodin | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rifater | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00948077 ↗ |
| Known as | Rifoldin | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rimactan | ChEMBL registry synonym — accepted as the source's own label CHEMBL374478 ↗ |
| Known as | Rimactane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02953847 ↗ |
| Known as | Rimapen | “The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days” NCT01854489 ↗ |
| Known as | RMP | “regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB)” PMID 24903795 ↗ May 20142“Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)” NCT07058090 ↗ “Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)” NCT00495326 ↗ |
| Action | Activate | “Nevirapine, efavirenz and rifampicin are known inducers of cytochrome P450 3A4” NCT00620438 ↗ |
| Modality | Small molecule | “is a semi-synthetic compound” NCT00816426 ↗ |
| Route | Oral | “ciprofloxacin, clofazimine, ethambutol, and rifampin (all taken orally)” NCT00000641 ↗ |
| Target | CYP3A4 | “co-administration of a potent CYP3A4 inducer rifampin” PMID 25047139 ↗ Jul 2014 |